Does Anthem (Elevance Health) Cover Retatrutide?

What Is Retatrutide and Why Are Patients Asking About Coverage Now?

Retatrutide is a once-weekly subcutaneous triple-agonist targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. Eli Lilly is developing it under the internal program name LY3437943. The Phase 2 trial published in the New England Journal of Medicine in 2023 reported 24.2% mean body-weight reduction at 48 weeks in participants receiving the 12 mg dose, a figure that exceeds published results for semaglutide 2.4 mg and tirzepatide at comparable timepoints [1].

That efficacy signal has driven a surge in patient inquiries to insurers before the drug is even approved. Patients who experienced partial responses on semaglutide (Wegovy) or tirzepatide (Zepbound) want to know whether their Anthem plan will cover the next generation of therapy.

Retatrutide is still an investigational agent as of mid-2025. Phase 3 trials under the TRIUMPH program are ongoing. No NDA or BLA has been approved by the FDA [2]. Without an approved label, Anthem cannot assign a formulary tier, publish a formal clinical policy bulletin (CPB), or process a standard prior authorization. Any coverage today must come through a named patient medical exception or a specially negotiated employer benefit.

The 338-participant Phase 2 trial used doses of 1 mg, 4 mg, 8 mg, and 12 mg weekly. Participants in the 12 mg arm achieved 24.2% weight loss versus 2.4% for placebo at 48 weeks (P<0.001) [1]. Serious adverse events occurred in 12% of the highest-dose group, most commonly gastrointestinal. Those tolerability data will shape the label and, in turn, the PA criteria Anthem eventually writes.

Retatrutide's Current FDA and Regulatory Status

The FDA has not approved retatrutide for any indication. The drug is classified as an investigational new drug (IND). Eli Lilly has not filed an NDA as of the date of this review [2].

Phase 3 data are expected to read out in 2025 and 2026 across the TRIUMPH trial series, which is evaluating retatrutide in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The FDA's own guidance on anti-obesity medication development, updated in 2023, requires at least 5% placebo-adjusted weight loss and a cardiovascular outcomes trial for full approval of chronic weight management agents [3].

Anthem's standard practice is to issue a formal CPB within 90 to 180 days of FDA approval for major drug classes. Until that CPB exists, automated PA systems cannot process a request for retatrutide under a standard pharmacy or medical benefit.

Patients who want to track FDA status should monitor the FDA Drug Approvals and Databases page directly [2].

How Anthem (Elevance Health) Covers Anti-Obesity Medications Generally

Understanding how Anthem handles approved GLP-1 and GIP/GLP-1 agents gives a reliable preview of how it will approach retatrutide once approved.

Anthem covers FDA-approved anti-obesity medications under a structured PA framework tied to its clinical policy bulletins. For semaglutide 2.4 mg (Wegovy), Anthem's CPB typically requires [4]:

1. A confirmed BMI ≥30, or BMI ≥27 with a documented comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.
2. Documentation of a supervised diet and exercise program for at least three months prior to the request.
3. Failure of or contraindication to at least one prior pharmacotherapy, most commonly orlistat, phentermine/topiramate, or naltrexone/bupropion.
4. A prescribing provider with documented experience managing chronic obesity.

For tirzepatide (Zepbound), approved by the FDA in November 2023, Anthem added step therapy requiring documented trial of semaglutide 2.4 mg or another approved GLP-1 agent in many of its commercial plan designs [5]. That precedent strongly suggests retatrutide will face at minimum a semaglutide or tirzepatide step before Anthem approves it.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines state: "Pharmacotherapy for obesity should be considered for all patients with a BMI ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity when lifestyle intervention alone is insufficient" [6]. Anthem's CPBs typically track AACE and Endocrine Society guidance closely, though the insurer adds utilization-management layers those guidelines do not require.

Prior Authorization Criteria Anthem Will Likely Apply to Retatrutide

No official Anthem CPB for retatrutide exists yet. Based on the pattern of existing Anthem CPBs for semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda), HealthRX's medical team projects the following criteria framework for retatrutide PA once the drug is approved:

Projected Anthem Retatrutide PA Criteria

| Criterion | Likely Requirement | |---|---| | Diagnosis | Obesity (ICD-10 E66.x) or overweight with comorbidity | | BMI threshold | ≥30, or ≥27 with T2D, hypertension, or OSA | | Prior diet program | ≥3 months documented supervised program | | Step therapy (drug) | Trial of semaglutide 2.4 mg or tirzepatide for ≥12 weeks | | Response threshold | <5% weight loss on prior agent, or intolerance | | Prescriber type | MD, DO, NP, or PA with obesity medicine or endocrinology documentation | | Renewal interval | Every 12 months with ≥5% weight loss from baseline |

This framework is an original clinical projection by the HealthRX medical team and should not be used as a substitute for Anthem's actual CPB, which will govern decisions once published.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy, co-authored by Dr. Caroline Apovian and colleagues, recommends against rigid step therapy when a patient has already failed or is intolerant to one approved agent: "Switching to an agent with a complementary mechanism is appropriate when the initial agent produces inadequate response" [7]. Whether Anthem will incorporate that flexibility into its retatrutide CPB is unknown, but citing this guideline in a PA letter may support a medical necessity argument.

Step Therapy Requirements: What the Evidence Says

Step therapy is the insurance practice of requiring patients to try lower-cost or longer-established drugs before a newer agent is approved. For retatrutide, step therapy is almost certain given Anthem's track record on tirzepatide and the drug's expected price at or above tirzepatide's list price.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [8]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% for placebo [9]. Retatrutide's Phase 2 data at 12 mg (24.2% at 48 weeks) sit above both, which means the clinical argument for moving to retatrutide after a partial response on tirzepatide will be data-driven and specific.

A patient who achieved only 8% weight loss on tirzepatide 15 mg over 24 weeks, despite full adherence, has a documentable inadequate response. That documentation is what PA appeal letters need. Providers should record the specific dose titrated, the duration at maximum tolerated dose, any side effects, and the percentage weight change from baseline. Anthem's appeal reviewers use those specifics, not general statements about treatment failure.

Several states have enacted step therapy protection laws that limit how many prior drug trials an insurer can require before approving a newer agent. As of 2025, at least 29 states have passed such legislation [10]. Patients in states with these protections may have a shorter required step sequence before retatrutide approval.

How to Appeal an Anthem Denial of Retatrutide

Anthem denials follow a three-stage process: internal appeal, external Independent Review Organization (IRO) review, and, in some cases, state insurance commissioner complaint.

Stage 1: Internal Appeal (Anthem) File within 180 days of the denial notice for pre-service denials. Include:

• A physician letter of medical necessity citing specific body-weight data, comorbidity burden, and prior drug trial outcomes with doses and durations.
• A copy of the relevant clinical guideline (AACE 2023 [6], Endocrine Society 2023 [7]).
• Peer-reviewed literature, including the Jastreboff et al. Phase 2 NEJM paper [1], documenting retatrutide's distinct mechanism and superior efficacy over approved agents.
• Documentation of step therapy completion (semaglutide or tirzepatide trial).

Anthem must respond to urgent pre-service appeals within 72 hours and non-urgent pre-service appeals within 30 days under the Affordable Care Act's internal appeal timelines [11].

Stage 2: External IRO Review If Anthem upholds the denial, patients may request an external review within four months of the final internal denial. The IRO is an independent entity contracted by the state insurance commissioner, not by Anthem. IRO decisions are binding on Anthem in most states. External review requests go through the Anthem member portal or by written request to the address on the denial letter.

Stage 3: State Insurance Commissioner Patients can file a complaint with their state's insurance department concurrently with an IRO request. This step adds regulatory pressure and creates a paper trail useful for any subsequent litigation.

For self-funded ERISA employer plans, external state IRO review may be limited. ERISA plans fall under federal jurisdiction, and appeals beyond the internal stage may require filing with the U.S. Department of Labor or initiating federal civil litigation. Consulting an insurance attorney or a patient advocacy organization is advisable for ERISA denials.

The FDA's drug labeling regulations require that the approved prescribing information be available to support PA and appeal documentation [2]. Once retatrutide is approved, the official label will specify the indication, dosing, and contraindications, all of which are material to the medical necessity argument.

Formulary Tier: What to Expect When Retatrutide Is Approved

Anthem uses a five-tier formulary structure in most of its commercial plans. Specialty drugs with a list price above roughly $600 per month typically land on Tier 4 (preferred specialty) or Tier 5 (non-preferred specialty). Tirzepatide (Zepbound) is currently placed on Tier 5 for many Anthem commercial plans, with a 30-day cost-share ranging from $150 to $600 after PA approval, depending on the specific plan design.

Retatrutide will almost certainly launch at a price comparable to or higher than tirzepatide given its Phase 2 efficacy data and the competitive market position Eli Lilly will seek. List price estimates from industry analysts range from $1,200 to $1,600 per month, though no official pricing has been announced. At that price point, a Tier 5 placement with 25% to 30% coinsurance could mean $300 to $480 per month out of pocket for members who have met their deductible.

Anthem's formulary exceptions process allows providers to request a lower cost-share tier if a non-preferred drug is medically necessary and no preferred alternative exists. For a patient with documented intolerance to both semaglutide and tirzepatide, a Tier 4 formulary exception request citing AACE guidelines [6] may reduce out-of-pocket costs.

Employer-sponsored self-funded plans set their own drug lists. A company's HR or benefits team can confirm whether retatrutide is covered and at what tier independently of Anthem's standard commercial formulary.

Manufacturer Savings Programs and Cash-Pay Options

No Eli Lilly savings card for retatrutide is currently available because the drug is not approved. Once approved, Eli Lilly will likely offer a co-pay assistance program similar to the Zepbound savings card, which currently caps monthly cost-share at $50 for eligible commercially insured patients [12].

Manufacturer co-pay cards generally cannot be used by patients enrolled in federal health programs (Medicare, Medicaid, TRICARE). Anthem Medicare Advantage members will not qualify for commercial savings programs under federal anti-kickback rules.

For patients willing to pay out of pocket before insurance coverage is established, compounding pharmacies have produced semaglutide and tirzepatide under FDA enforcement discretion policies during shortage periods. The FDA has stated that compounded versions of drugs that are not on the drug shortage list do not qualify for the compounding exemptions under 503A and 503B of the Federal Food, Drug, and Cosmetic Act [13]. Retatrutide is not approved and not on any shortage list, meaning compounding of retatrutide would not be legally permissible under current FDA policy.

Patients seeking retatrutide outside of clinical trials have no legal commercial source as of mid-2025.

Clinical Trials as a Coverage Alternative

Enrollment in a Phase 3 TRIUMPH trial provides access to retatrutide at no drug cost, with study-related visits and labs covered by the sponsor. ClinicalTrials.gov lists active TRIUMPH studies including TRIUMPH-1 (NCT05929404) and TRIUMPH-4 (NCT06015841), enrolling adults with BMI ≥30 or BMI ≥27 with comorbidities [14].

Trial participation is not insurance coverage, but for patients who meet eligibility criteria, it is the only reliable access pathway as of mid-2025. Providers should check eligibility criteria carefully; prior GLP-1 use may be an exclusion in some TRIUMPH substudies.

The NIH's clinical trial registry is the authoritative source for current enrollment status [14].

How Anthem's Policy May Differ by Plan Type

Anthem sells several distinct product lines, and coverage policies vary across them.

Commercial fully insured plans follow Anthem's standard CPBs. Once Anthem publishes a retatrutide CPB, fully insured plan members will be subject to whatever PA criteria and formulary tier Anthem sets.

Self-funded employer plans (ERISA) use Anthem as a third-party administrator. The employer decides the benefit design, including whether to include retatrutide. Some large employers, particularly those with self-insured benefit programs and dedicated pharmacy benefit managers (PBMs), may add retatrutide to their formulary independent of Anthem's corporate policy.

Medicaid managed care (Anthem/Wellpoint Medicaid) follows state Medicaid rules. Most state Medicaid programs have historically excluded anti-obesity medications from coverage, though the Biden administration's 2025 proposed rule to require Medicaid coverage of GLP-1s for obesity changed that trajectory for some states [15]. Retatrutide availability under Medicaid will depend on both federal rule finalization and state-level implementation.

Medicare Advantage (Anthem Blue Cross) is governed by CMS rules. The Inflation Reduction Act of 2022 did not include obesity drugs in its Medicare drug coverage expansions. CMS's 2025 final rule allows Medicare Part D plans to cover GLP-1s for obesity on an optional basis starting in 2026, meaning Anthem Medicare Advantage PDP sponsors may or may not add retatrutide when it is approved [16].

What Providers Should Document Today to Prepare for Retatrutide PA

Even before retatrutide is approved, providers treating patients who may eventually need it should build their charts now. Anthem's PA reviewers and appeal clinicians look at a longitudinal record, not just the current visit.

Providers should document at each visit:

• Current BMI and body weight with date.
• Active obesity-related comorbidities with ICD-10 codes (E66.01 for morbid obesity, E11.x for type 2 diabetes, I10 for hypertension).
• Current anti-obesity medication, dose, duration, and response measured as percentage change from a recorded baseline weight.
• Adverse effects experienced at each dose level.
• Dietary and lifestyle interventions attempted, with program names, start dates, and outcomes.
• Any psychological, physical, or economic barriers to adherence.

The Obesity Medicine Association's practical guide to PA documentation, consistent with AHA/ACC cardiovascular risk guidelines, recommends quantifying cardiovascular risk reduction as a supporting argument in PA letters for obesity pharmacotherapy [17]. A patient with a 10-year ASCVD risk above 10% and inadequate response to a prior GLP-1 has a stronger medical necessity case than BMI alone.

Complete documentation submitted at the time of initial PA reduces denial rates and avoids the delay of an appeal cycle that can run 60 to 120 days.